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Abstract
Background: Caerulomycin A (CaeA) is a known antifungal and antibiotic agent. Further, CaeA is reported to induce the
expansion of regulatory T cell and prolongs the survival of skin allografts in mouse model of transplantation. In the current
study, CaeA was purified and characterized from a novel species of actinomycetes, Actinoalloteichus spitiensis. The CaeA was
identified for its novel immunosuppressive property by inhibiting in vitro and in vivo function of T cells.
Methods: Isolation, purification and characterization of CaeA were performed using High Performance Flash
Chromatography (HPFC), NMR and mass spectrometry techniques. In vitro and in vivo T cell studies were conducted in
mice using flowcytometry, ELISA and thymidine-[methyl-3H] incorporation.
Results: CaeA significantly suppressed T cell activation and IFN-c secretion. Further, it inhibited the T cells function at G1
phase of cell cycle. No apoptosis was noticed by CaeA at a concentration responsible for inducing T cell retardation.
Furthermore, the change in the function of B cells but not macrophages was observed. The CaeA as well exhibited
substantial inhibitory activity in vivo.
Conclusion: This study describes for the first time novel in vitro and in vivo immunosuppressive function of CaeA on T cells
and B cells. CaeA has enough potential to act as a future immunosuppressive drug.
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Introduction
Immunosuppression is the only available therapy for patients
undergoing allogeneic organ transplantation. Thus, immunosup-
pressive drugs play a crucial role in the survival of allogeneic tissue
grafts. In the 20th century, many new molecules have been
discovered to be used as immunosuppressive agents. Cyclosporine
A (CsA), tacrolimus, rapamycin and mycophenolate mofetil
(MMF) are the drugs that have proven immunosuppressive
activity in patients [1].
Tacrolimus and CsA are the calcineurin inhibitors (CNI) [2].
The introduction of calcineurin inhibitors was a revolutionary
event in the history of transplantation [3]. It not only dramatically
improves the outcome of graft acceptances, but also transplanta-
tion of heart, liver and pancreas became possible. Besides these
advantages, CNI are also associated with adverse side effects.
Those include nephrotoxicity, malignancy, and hypertension
[4,5,6]. This compromises the overall benefits of the drug during
long-term application. The immunosuppressive agents MMF and
sirolimus have been shown to be well tolerated and effective
alternative for CNI [7,8]. Recent studies revealed that these drugs
have severe side-effects during long-term clinical applications
[9,10]. Consequently, invention of novel immunosuppressive
molecules with better mode of action and minimum side-effects
are urgently desired for patients undergoing long-term treatment.
Most of the immunosuppressive drugs are discovered from
secondary metabolites of microorganisms [11–13]. In search of a
novel immunosuppressive drug, we screened various extracts
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secreted by microorganisms collected from different niches of
India. Interestingly, we discovered bioactive compound produced
by a new strain of actinomycetes. This was named as
Actinoalloteichus spitiensis (A. spitiensis) [14]. The compound
exhibited potent immunosuppressive property on T cells. The
NMR data revealed that the active compound was Caerulomycin
A (CaeA).
Recently, we have described a novel role of CaeA in inducing
the generation of regulatory T cells (Tregs) [15]. Further, it
suppressed the mixed lymphocyte reaction and prolonged the
survival of skin allografts in experimental model of transplantation
[16]. In the current study, we report that CaeA effectively
inhibited in vitro and in vivo activity of T cells and B cells. Both
these cells play an imperative role in the graft rejection. Therefore,
CaeA may have an important application as an immunosuppres-
sive drug in the future.
Materials and Methods
Mice
Inbred female BALB/c, C57BL/6J and C3He mice, 6–8 weeks
old were obtained from the institute’s animal facility. The animals
were housed under normal conditions and food and water were
available ad libitum.
Ethics statement
The animal study was approved by Institutional Animal Ethical
Committee (IAEC) of Institute of Microbial Technology, Chandi-
garh. These experiments were performed according to National
Regulatory Guidelines issued by Committee for the Purpose of
Experiments on Animals (CPCSEA), Ministry of Environment and
forest, Govt. of India.
Chemicals and reagents
All cytokines and Abs used for ELISA and flowcytometry were
procured from Becton Dickinson (Franklin Lakes, NJ), or
otherwise mentioned. Growth media components were purchased
from Hi-media (Mumbai, India) and Difco (Detroit, MI). Sodium
acetate, lysozyme, proteinase K, RNase A, saponin, paraformal-
dehyde, CsA and other fine chemicals were purchased from
SIGMA-ALDRICH (St. Louis, MO). CaeA was either procured
from LKT Laboratories (St. Paul, MN) or purified from
actinomycetes A. spitiensis. Aluminium sheets pre-coated with
silica gel 60 F254 were from Merck (Darmstadt, Germany). Fetal
calf serum (FCS) was purchased from Harlan Sera Lab (Crawley
Down, Great Britain). RPMI 1640, DMEM, HBSS and APO-
BrdU TUNEL assay kit were bought from Invitrogen (Carlsbad,
CA). L-glutamine, L-pyruvate, penicillin, concanavalin A and
streptomycin were procured from Serva (Heidelberg, Germany).
Thymidine-[methyl-3H] was the product of Amersham Pharmacia
Biotech AB (Uppsala, Sweden).
Medium
Cells were cultured in RPMI 1640 or DMEM medium
supplemented with 10% FCS, L-glutamine (2 mM), penicillin
(50 mg/ml), streptomycin (50 mg/ml), HEPES (100 mM) and 2-
mercaptoethanol (0.05 mM).
Fermentation of CaeA
CaeA was isolated from Actinoalloteichus spitiensis sp. nov. [14].
The stock culture of the organism was inoculated into a 500 ml
Erlenmeyer flask containing 100 ml of the seed medium composed
of (per litre): glucose: 5.4 g, yeast extract: 4.8 g, malt extract: 8.5 g
and CaCO3: 3 g (pH- 8.0). After incubation at 28uC for 48 h on a
rotary shaker at 220 rpm, vegetative culture was transferred at a
rate of 5% v/v into five 1L flasks containing 200 ml of medium.
The seed culture thus obtained was transferred into a 20L
fermenter containing 14L of seed medium. Fermentation was
carried out at 28uC, 300–350 rpm agitation and 1 vvm of
aeration. The growth is represented in terms of packed mycelial
volume (PMV) measurement. CaeA production was monitored by
colorimetric quantification method. In 2 ml of culture broth, 2 ml
of 10 mM ferrous ammonium sulphate solution was added
followed by 1 ml of 1% Na2CO3. Extraction of this solution was
done with 5 ml of n-butanol. The absorbance of clear solution was
read at 532 nm and finally compared with the standard CaeA.
Residual sugar was determined by the 3, 5-dinitrosalicylic acid
(DNS) method using glucose as standard [17].
Purification and structure elucidation of CaeA
After fermentation, ethyl acetate extraction of the culture broth,
and concentration in vacuo was done to obtain semisolid crude
residue. The compound was purified by using HPFC (Horizon
HPFC system, Biotage, San Francisco, CA) on silica gel (32–
63 mM, 60 A˚). Column was eluted with benzene:acetone (3:1).
The purity of the compound was checked by TLC and HPLC. For
structure elucidation, standard techniques like Proton Magnetic
Resonance Spectrometry (1HNMR), 13C NMR Spectrometry (13C
NMR), Mass Spectrometry (MS) and Infrared Spectrometry (FT-
IR) were used.
Estimation of cytokines
The cytokines IL-2, IL-5, IL-10, TGF-b and IFN-c in the
culture SNs and serum were estimated by sandwich ELISA,
according to the manufacturer’s instruction. Briefly, 96w ELISA
plates were coated (50 ml/well) with anti-IL-2 (4 mg/ml), anti-IL-5
(6 mg/ml), anti-IL-10 (6 mg/ml), anti-TGF-b (4 mg/ml) and anti-
IFN-c (4 mg/ml) Abs, in phosphate buffer (pH 9.2, pH 6 for IL-
10) and incubated for 12 h at 4uC. Later, the plates were blocked
with BSA (1%, 100 ml/well). ELISA plates were incubated with
culture SNs (50 ml/well) and their respective recombinant cytokine
standards (40–2000 pg/ml) for 12 h at 4uC. These plates were
treated with their corresponding biotin conjugated secondary Abs,
followed by streptavidin-HRP. Plates were developed using
substrate H2O2 and chromogenic agent OPD (o-phenylenedi-
amine). The reaction was stopped by mixing equal volume of 7%
H2SO4. Optical density (OD) of the color developed was
measured at 495 nm. Usual steps of incubations and washings
using PBS/Tween-20 (0.05%) were followed at each step. The
level of cytokines was estimated by plotting standard curve using
recombinant cytokines. Values are expressed as pg/ml. The same
procedure was followed for measuring isotypes IgG1 and IgG2a in
the serum using appropriate reagents.
Expression of CD69 on the surface of CD4 T cells by
flowcytometry
The cells were harvested from the cultures and Fc receptor was
blocked with anti-CD16 Ab, followed by staining with fluoro-
chrome conjugated anti-CD4 and CD69 Abs and their isotype-
matched controls for 30 min at 4uC. Usual steps of washings were
performed at each stage using flowcytometry buffer (PBS 1X+2%
FCS). Finally, cells were fixed in PBS containing paraformalde-
hyde (1%). The cells were acquired utilizing BD FACSCalibur,
and analysis was performed with the help of BD FACSDiva
software.
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Cell cytotoxicity assay
CD4 T cells were stimulated with anti-CD3 and CD28 Abs.
The cultures were treated with CaeA (0.15–0.62 mM) for 48 h.
Later, cytotoxicity of drug treatment was measured by TUNEL
assay (APO-BrdU TUNEL assay kit), according to the manufac-
turer’s instruction. Briefly, cells were harvested and media
components were removed by washing with excess quantity of
PBS, followed by fixing them in paraformaldehyde (1%). Later,
the cells were incubated in ethanol (70%) at 220uC for 18 h. The
nicked ends of DNA in apoptotic cells were labelled with BrdU for
60 min at 37uC followed by detection with Alexa fluor 488
labelled anti-BrdU Abs. These cells were counter stained with PI/
RNaseA staining buffer. The apoptotic human lymphoma cell line
recommended by assay kit was used as positive control. Cells were
acquired in BD FACSCalibur and analysis was performed by BD
FACSDiva software.
Proliferation and reversibility assay of mitogen
stimulated T cells cultured with CaeA
ConA (2 mg/ml) stimulated splenocytes (SPC) (26105/well)
from BALB/c mice were cultured with increasing concentrations
of CaeA (0.04–0.31 mM) in triplicate in ‘U’ bottomed 96w
microtitre tissue culture plate in RPMI/FCS-10% (200 ml). In
control cultures, cells were incubated with only ConA. After 48 h,
the cultures were pulsed with thymidine-[methyl-3H] (0.5 mCi)
and harvested 16 h later by automatic 96 well plate cell harvester
(Tomtech, Hamden, CT). Radioactivity incorporated was mea-
sured by liquid scintillation counting (1450 Micro Beta TriLux
Microplate counter, PerkinElmer, Waltham, MA).
In parallel, the similar cultures were set as indicated in the case
of T cell proliferation. After 48 h, cells (26105/well) were washed
36with 16PBS and restimulated with ConA (2 mg/ml) for 48 h.
The proliferation was measured as mentioned above. The
proliferation was directly proportional to the radioactivity
incorporated and data were expressed as counts per minute (cpm).
In vivo toxicity assay
The in vivo toxicity was performed by feeding the mice with
different doses (0.25–25 mg/kg body weight) of CaeA for 14 days.
Throughout the study various parameters like body weight, food
and water intake was monitored. At the end of the study, mice
were sacrificed and weight of various organs (liver, heart, kidney
and spleen) was measured. Organs of animals were also examined
for abnormalities by gross pathology. The in vivo toxicity
experiments were performed at the National Institute of Pharma-
ceutical Education and Research, Mohali, India.
Figure 1. CaeA suppresses T cell activation and IFN-c secretion. CD4 T cells stimulated with anti-CD3 and CD28 Abs were incubated with
indicated concentrations of CaeA for 48 h. (A) Flowcytometric histogram represents CD69 expression. Value in the inset indicates percentage; (B) bar
diagram depicts decreased percentage of CD4 T cells expressing CD69; (C) ELISA data depicted as pg/ml shows decrease in IFN-c secretion by CaeA.
‘*’ represents p,0.05. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0107051.g001
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Cell cycle analysis
Jurkat cells were synchronized by serum starvation overnight
and then exposed to CaeA and CsA (0.15 mM) for 24 h and 48 h.
Thereafter, cells were washed, and fixed with ethanol (70%).
Later, ethanol was removed and cells were suspended directly in
staining solution (propidium iodide: 25 mg/ml, RNase A: 0.1 mg/
ml, TritonX-100: 0.05% in PBS), and incubated at RT for 20 min
in darkness. Immediately, cells were acquired using BD FACSCa-
libur and data were analyzed with the help of ModFit LT software.
In vivo T cell response
The emulsion of antigen ovalbumin (OVA) (2 mg/ml in PBS)
was prepared in equal volume of complete Freund’s adjuvant.
Emulsion (100 ml/mouse) was injected intraperitoneally (i.p.) in
BALB/c mice. After 7 days, the animals were given a booster dose
of antigen (50 ml/mouse) emulsified in incomplete Freund’s
adjuvant. Different sets of experimental and control groups (5
mice/group) of animals were orally fed CaeA (2.5 mg/kg body
weight) daily for 7 days. The control groups were administered
CMC and PBS. Later, mice were sacrificed and SPC (26106/ml)
were pooled and in vitro cultured with increasing concentrations
of OVA. After 48 h, these cultures were pulsed with thymidine-
[methyl-3H] (0.5 mCi/ml) for 16 h. Later, cells were harvested and
radioactivity incorporated was measured by liquid scintillation
counting and expressed as cpm.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software. The differences between two values were compared by
Unpaired Student’s ‘t’ test two tailed. In case of comparison
between two groups, two-way ANOVA was used for measuring
significant difference.
Results
Fermentation, purification and structural elucidation of
CaeA
A time course fermentation analysis plot for organism A.
spitiensis (Figure S1 A, B); showing increase in the growth and
CaeA production and decrease in residual sugar over time.
Maximum growth of the strain was observed after 24 h and CaeA
yield peaked near 72 h. Broth obtained after 72 h was extracted
with ethyl acetate and concentrated in vacuo. HPFC was
performed to purify CaeA using benzene:acetone (3:1). TLC
showing the purification profile of CaeA (Figure S1 C). Further,
based on NMR, IR and mass spectral data, the identified
compound was CaeA (Figure S2). The result corresponds well
with the already reported data on CaeA [18–20]. Structure was
further confirmed (1HNMR) by converting CaeA into methyl
ether by its reaction with methyl iodide in the presence of
anhydrous potassium carbonate in anhydrous acetone (Table S1).
Induction of the suppression of T cell response by CaeA
In the initial phase of the study, we checked the immunosup-
pressive activity of CaeA on T cells on the expression of the
activation marker CD69, which is upregulated during T cell
activation [21]. Interestingly, we observed significant (p,0.05)
decline in the display of CD69 by CaeA (Figure 1 A, B). The
change was seen in a dose dependent manner. CsA, an
immunosuppressive drug, known to inhibit CD69 expression on
the activated T cells was used as a positive control [22]. Since
CaeA considerably retarded CD69 expression we next evaluated
its influence on the IFN-c secretion. We found that CaeA
markedly (p,0.05) decreased the secretion of IFN-c (Figure 1 C).
The inhibition in the IFN-c secretion by CaeA was noticed in a
dose dependent fashion. Whereas, no change in the IFN-c level
was noted in the control cultures incubated with DMSO alone.
These results may provide some insight into the mode of action of
immunosuppression by CaeA by downregulating the expression of
CD69. The specificity of CaeA on T cell activity was established
by analyzing LPS induced macrophage activation. CaeA treat-
ment does not affect the expression of CD86 and nitric oxide (NO)
and proinflammatory cytokines IL-6 and TNF-a release from
macrophage (Figure S3).
CaeA inhibits IL-10 but not TGF-b secretion
CaeA significantly (p,0.0001) retarded the yield of IL-10 by
CD4 T cells activated by anti-CD3 and CD28 Abs (Figure 2A).
No change was noted in the case of TGF-b release (Figure 2B).
These results indicate that CaeA mediated inhibition of the T cell
activation and IFN-c secretion is not due to the involvement of
either IL-10 or TGF-b.
Figure 2. CaeA inhibits the production of IL-10. CD4 T cells
stimulated with anti-CD3 and CD28 Abs were cultured with different
concentrations of CaeA for 48 h. Later, the cytokines level was
estimated by ELISA. Bar diagrams represent mean+SD of (A) IL-10; (B)
TGF-b estimated in the culture supernatants. ‘*’, ‘***’ denote p,0.05,
p,0.0001, respectively. Results shown are of two independent
experiments.
doi:10.1371/journal.pone.0107051.g002
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Inhibition of T cell response by CaeA is not due to
cytotoxicity
We were concerned that CaeA mediated inhibition of IFN-c
secretion and CD69 expression was due to immunosuppression
and not cytotoxicity. Hence, we did TUNEL assay. The results
confirmed that CaeA is not toxic to T cells, as evidenced by lesser
percentage of BrdU+ cells by flowcytometry data (Figure 3A, B).
The studies on T cells reversibility after removal of CaeA also
supported that CaeA is not toxic at the concentration, which is
inducing immunosuppression. The ConA stimulated T cell
proliferation was significantly (p,0.0001) suppressed by CaeA
treatment (Figure 3C). However, removal of CaeA after 48 h of
treatment from the cultures could still revert back T cells to
normal state, as evidenced by proliferation upon activation with
ConA (Figure 3D).
CaeA induced the suppression of T cells by arresting the
cell cycle at G1 phase
We observed that CaeA inhibited T cell proliferation by
arresting the cell cycle at G1 phase (Figure 4A, B), as documented
by the increase in PI incorporation (70%), compared to vehicle
(DMSO) control (49%) at 48 h. The concentration 0.15 mM of
CaeA was chosen in the experiment, since it induced significant
decline in the proliferation of T cells (Figure 3C). An equimolar
concentration of CsA was used as a positive control.
CaeA induced the in vivo suppression of T cell
proliferation
Suppression of the activation of antigen reactive T cells and B
cells has therapeutic implication in inhibiting the undesired
immune response [23,24]. Hence, we next wanted to check
whether CaeA can suppress the activation of antigen reactive T
Figure 3. CaeA is not toxic to CD4 T cells. Purified CD4 T cells stimulated with anti-CD3 and CD28 Abs were cultured with different
concentrations of CaeA for 48 h. Later, frequency of CD4 T cells undergoing apoptosis was analyzed. (A) Flowcytometric histograms represent BrdU
incorporation (APO-BrdU TUNEL assay) of cells undergoing apoptosis. Diagram also shows positive control; (B) bar diagram denotes flowcytometry
data of the percentage of cells undergoing apoptosis. Value in the inset of histogram depicts the percentage of cells; (C) inhibition in the proliferation
of T cells by different doses of CaeA, monitored by thymidine-[methyl-3H] incorporation and expressed as cpm; (D) bar diagram signifies the
reversibility in T cell proliferation after the removal of CaeA. Results expressed as percentage (A); mean6SE (B-D) are from three independent
experiments. ‘*’, ‘***’ specify p,0.05, p,0.0001, respectively.
doi:10.1371/journal.pone.0107051.g003
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cells and B cells in vivo. Our experimental results showed that T
cells obtained from antigen-primed mice, which were orally fed
CaeA for 7 d, exhibited substantial inhibition (p,0.0001) in the
proliferation (Figure 5A). Further, significant decrease (p,0.0001)
was seen in the serum levels of IFN-c and IL-5 (Figure 5B), as well
as in the SNs collected from the cells cultured in vitro with antigen
and CaeA (Figure 5C). Furthermore, noticeable retardation (p,
0.0001) in the level of serum IgG1, IgG2a and IgG2b was
measured in the CaeA treated mice (Figure 6A). We also observed
substantial (p,0.0001) decline in the proliferation of LPS
stimulated B cells in vitro and treated with CaeA (Figure 6B).
No change was observed in the control groups administered with
either PBS or CMC (Figure 5, 6). Since proliferation of both T
cells and B cells is inhibited by the CaeA, we conjecture that the
reduced Ab titer was because of the inhibitory effect on both the
cells.
We also monitored the in vivo toxicity of CaeA on mice by
recording the change in different parameters (mortality, body
weight, gross pathology, food and water intake and weight of
organs) for 14 days. Except minor change in liver weight, CaeA
Figure 4. CaeA induces cell cycle arrest at G1 phase.
Synchronized T cells (Jurkat) were incubated with CaeA for 24 h and
48 h and cell cycle analysis was performed. (A, B) Flowcytometry and
histograms depict the percentage of cells at different stages (G1, G2
and S) of cells cycle. Values in the (A) inset of the histograms represent
percentage of cells; (B) bar diagrams as mean6SE of the data obtained
from flowcytometric analysis for cell cycle arrest at 24 h and 48 h.
Results are representative of two independent experiments. ‘***’
indicates p,0.0001.
doi:10.1371/journal.pone.0107051.g004
Figure 5. CaeA treatment inhibits in vivo T cell activation.
Animals immunized with antigen were treated with CaeA and
suppression in the activation of T cells was examined. (A) Line diagrams
designate the suppression in antigen specific T cell proliferation,
measured by thymidine-[methyl-3H] incorporation; (B, C) bar diagram
refers to the estimation of IFN-c and IL-5 (pg/ml) by ELISA in the (B)
serum and (C) culture SNs. Results are representative of three
independent experiments. Error bars indicate mean6SD. ‘***’ specifies
p,0.0001.
doi:10.1371/journal.pone.0107051.g005
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treatment does not induce any significant variation in any of the
parameters studied (Figure S4).
CaeA mode of action is different from calcineurin
inhibitors
It was important for us to monitor whether the mode of
immunosuppressive activity of CaeA was same as observed in the
case of CsA. CsA exerts its inhibitory action through calcineurin
pathway [25]. Interestingly, inhibition in the secretion of IL-2 was
seen with CsA but not CaeA (Figure 7A). IL-2 secretion is an
indicator of the activation of calcineurin pathway (25). Further, we
could rescue the inhibition in the proliferation induced by CsA by
addition of exogenous IL-2 (Figure 7B). In contrast, no change
was measured in the case of CaeA (0.15 mM). Thus, the results
depicted that the mechanism of action of CaeA is distinct from
CsA.
Discussion
Actinomycetes are one of the most competent microorganisms
capable of producing secondary metabolites with multiple
biological activities like antifungal, immunosuppressive, antibac-
terial, antiviral, anticancer and anti-inflammatory, etc. [26].
CaeA used in this study was identified, isolated and purified from
a novel species A. spitiensis during screening of bioactive
molecules.
In allogeneic organ transplantation, the immune system of
recipient will recognize the transplanted organ as foreign antigen
and elicit immune response. The professional antigen presenting
cells (DCs) from donor graft will migrate to the secondary
lymphoid organs. In the secondary lymphoid organs these DCs
will activate the naı¨ve T cells to become effector T cells [27]. T
cells play a fundamental role in the initiation and regulation of
immune responses [28]. The role of T cells is well established in
autoimmune diseases and graft rejection [29,30]. T cells under-
gone activation will emerge from lymph nodes and infiltrate the
implanted organ and orchestrate the process of rejection. The
effector T cells generated against the alloantigen will undergo
activation and produce IFN-c. Immune cells like macrophages,
neutrophils and B cells will respond to the IFN-c, leading to the
tissue destruction. B cells after interacting with T cells will secrete
the antibody against allograft and are also involved in the graft
rejection. Therefore, it is crucial to suppress the activation of T
cells.
Figure 6. CaeA retards the in vivo function of B cells. Antigen primed mice were treated with CaeA and the inhibition in the function of B cells
was monitored. (A) Bar diagram denotes yield of IgG1, IgG2a and IgG2b isotypes, estimated by ELISA in the serum; (B) The proliferation B cells treated
in vitro with doses of CaeA was examined by radioactivity incorporation and expressed as cpm. Results are representative of three independent
experiments. Error bars indicate mean6SD. ‘**, ‘***’ specify p,0.005, p,0.0001, respectively.
doi:10.1371/journal.pone.0107051.g006
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The undesired immune response elicited against the engrafted
tissue is suppressed with the help of immunosuppressive drugs.
Existing treatment to suppress the alloreactivity largely depends on
drugs like azathioprine, mycophenolate mofetil, CsA, tacrolimus,
rapamycin, corticosteroids, etc. [1]. These drugs are toxic and
associated with severe side-effects. Hence, there exists a necessity
to search new drugs, which can efficiently exert immunosuppres-
sion without inflicting much harm to the patients. In this
connection we have earlier demonstrated the suppressive role
CaeA by inducing the generation of Tregs [15]. Further, we have
also shown that CaeA suppressed the activation of allogeneic T
cells and substantially prolonged the survival of mouse skin
allografts [16]. In the present study we attempted to analyse the
immunosuppressive activity of CaeA on polyclonal and antigen
reactive T cell and B cell populations. Following major results
have emerged signifying that CaeA i) downregulates the expression
of CD69; ii) suppresses the secretion of IL-5, IL-10, IFN-c; iii) is
not toxic at the optimum dose; iv) arrests the T cell cycle at G1
phase; v) impedes the function of antigen reactive T cells and B
cells; vi) mediates immunosuppression through mechanism distinct
from calcineurin inhibitors.
Interestingly, CaeA suppresses CD69 expression on activated T
cells. The generation of immune response begins with T cell
activation [31]. The activated T cells upregulate the expression of
CD69 on their surface [21]. Recent studies suggest that CD69
negatively regulate the Tregs by favouring effector T cell
differentiation [32]. Therefore, inhibition of T cell activation is a
potential approach to treat graft rejection and autoimmune
diseases [33–35].
On the basis of cytokines profile, CD4 T cells can be subdivided
into Th1 and Th2 cells. Th1 cells mainly produce IL-2 and IFN-c
and are responsible for cell-mediated immunity. In contrast, Th2 cells
chiefly secrete IL-4 and IL-5 and are responsible for humoral
immunity [36]. Further, Th1 dominated immune responses are often
associated with inflammation and tissue injury; because IFN-c
recruits and activates macrophages and neutrophils. The typical
inflammatory reaction is delayed type hypersensitivity, which is also
Th1-mediated and accompanied by host tissue damage [37,38]. IFN-
c also antagonize the generation of Tregs [39]. We observed that
CaeA notably suppressed the IFN-c secretion from activated T cells.
After receiving antigen stimulation, T cells undergo clonal
expansion. Rapamycin is a very well-known immunosuppressive
drug, which diminishes the T cell proliferation by preventing the
cells to enter from S to G1 phase [40]. CaeA exhibited homology
with rapamycin in arresting the T cells at G1 phase of the cell
cycle. Likewise, CaeA and rapamycin also induced the generation
of Tregs [15,41]. Recently, we have demonstrated that CaeA
considerably up-regulated the expression of Foxp3 on CD4 T cells
and decreased the frequency of Th1 and Th17 cells. The possible
mechanism identified indicated that CaeA obstructed IFN-c-
induced STAT1 signaling by enhancing the display of SOCS1 and
increased TGF-b mediated Smad3 function. Consequently,
supported the generation of Tregs [15].
The in vitro findings of immunosuppressive influence of CaeA
on T cells gave considerable impetus to our confidence when
similar results were replicated in vivo, as well. The decrease in the
proliferation of T cells in the CaeA treated group of animals upon
antigen challenge may be due to induction of Tregs by CaeA, as
reported in our recent observation [15]. The role of antibodies has
also been implicated in the graft rejection and many autoimmune
diseases [42,43]. It is also very well established fact that when Th1
and Th2 cells interact with B cells, they mainly produce IgG2a
and IgG1, respectively. Consequently, inhibition in the secretion
of IgG1 and IgG2a in vivo further authenticates our observation
that CaeA suppresses the activation of Th2 and Th1 cells. It is
worth to mention here that CaeA suppressed the production of IL-
5 and IFN-c, which are the indicator cytokines for Th1 and Th2
cells [36].
Lastly, we demonstrated that the mechanism of action of CaeA
is quite distinct from immunosuppressive drug CsA. Since, CaeA
does not follow the calcineurin pathway, therefore making it a
unique and potent immunosuppressive molecule. Consequently, it
has enough potential in future for treating autoimmune diseases,
allergies and graft rejection.
Figure 7. CaeA mediated immunosuppression is different from
calcineurin inhibitors. CD4 T cells stimulated with anti-CD3 and
CD28 Abs were incubated with CaeA and CsA and monitored for (A) IL-2
secretion; (B) modulation of the proliferation by CaeA and CsA in the
presence or absence of IL-2. Data shown as mean6SE are represen-
tative of 3 independent experiments. ‘***’ signify p,0.0001 and ns as
non-significant.
doi:10.1371/journal.pone.0107051.g007
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Supporting Information
Figure S1 CaeA production and its purification. (A) Micelle
structure of A. spitiensis [2006]; (B) kinetics of the growth and
production of CaeA by A. spitiensis; (C) TLC analysis of fractions
obtained from High Performance Flash Chromatography (HPFC).
(TIF)
Figure S2 Structure elucidation of the isolated compound. 13C
NMR spectrum of CaeA in DMSO, (75 MHz), full spectrum
(Fig. 2.1A), expanded portion of spectrum A starting from 105 to
165 ppm (Fig. 2.1B); 1H NMR spectrum of CaeA in DMSO,
(300 MHz) Full spectrum (Fig. 2.2A), expanded portion of
spectrum A starting from 7.2 to 9.0 ppm (Fig. 2.2B); 1H NMR
spectrum of CaeA in CDCl3, (300 MHz) (Fig. 2.3A), full
spectrum, expanded portion of spectrum A starting from 7.2 to
8.8 ppm (Fig. 2.3B); 1H NMR spectrum of CaeA’s methyl
derivative in CDCl3 (300 MHz) (Fig. 2.4A), full spectrum,
expanded portion of spectrum A starting from 7.1 to 8.9 ppm
(Fig. 2.4B); Distortionless Enhancement by Polarization Transfer
(DEPT), DEPT-90 (Fig. 2.5A), DEPT-135 experiments by using
Bruker (300 MHz) (Fig. 2.5B); Mass spectrum of CaeA (Fig. 2.6),
the molecular weight of CaeA is 229.09 by using Double focusing
Mass spectrophotometer (VG,70S, 250). The structure of CaeA
(Fig. 2 C).
(TIF)
Figure S3 CaeA does not affect the macrophage function.
Peritoneal macrophages were stimulated with LPS and incubated
for 48 h. (A) Flowcytometric histograms represent CD86 expres-
sion. ELISA data shows release of (B) TNF-a; (C) IL-6; (D) NO
production by Griess method. Results are denoted as percentage
(A); mean6SD (B–D). ‘ns’ stands for non-significant. Data are
representative of 2–3 independent experiments.
(TIF)
Figure S4 CaeA administration in mice does not induce toxicity.
Acute toxicity test was performed by feeding animals with
indicated concentrations of CaeA. (A) Bar diagram represents
the weight of animals at different time intervals. Dot plots depict
the weight of (B) liver, (C) heart, (D) kidney, (E) spleen. Bar
diagrams signify intake of (F) food; (G) water at different time
intervals. Results are represented as mean6SD with 4–6 mice per
group. ‘ns’ stands for non-significant.
(TIF)
Table S1 1H and 13C NMR spectral data of Caerulomycin A
(CaeA). 1H and 13C NMR were recorded on BruckerAvance300
(300 MHz for 1H; 75 MHz for 13C) spectrometer using CDCl3 or
DMSO as solvent. Tetramethylsilane (TMS)/residual CHCl3 were
used as internal standard. Chemical shifts d are reported as
downfield from TMS. Values of coupling constant J are reported
in Hz.
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